Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer

Matthew Mutch

Research output: Contribution to journal › Comment/debate

Fingerprint

Dive into the research topics of 'Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer'. Together they form a unique fingerprint.